Tema Etfs LLC Increases AbbVie Stake by 7.2%

The institutional investor now owns over 51,000 shares of the pharmaceutical company.

Apr. 2, 2026 at 10:56am

Got story updates? Submit your updates here. ›

Tema Etfs LLC, an investment management firm, increased its stake in AbbVie Inc. (NYSE:ABBV) by 7.2% in the fourth quarter of 2025. The firm now owns 51,789 shares of the pharmaceutical company's stock, valued at $11.8 million.

Why it matters

AbbVie is a major pharmaceutical company with a diverse portfolio of drugs, including immunology, oncology, and women's health products. Institutional investors like Tema Etfs closely monitor and adjust their positions in large-cap healthcare stocks like AbbVie to manage risk and capitalize on market opportunities.

The details

Tema Etfs LLC added 3,475 shares of AbbVie to its investment portfolio during the fourth quarter. The firm's total holdings in AbbVie now represent about 0.9% of its overall assets under management. AbbVie's stock price has fluctuated between $164.39 and $244.81 over the past 52 weeks.

  • Tema Etfs LLC increased its AbbVie stake in the fourth quarter of 2025.
  • AbbVie's stock price has ranged from $164.39 to $244.81 over the past year.

The players

Tema Etfs LLC

An institutional investment management firm that owns a portfolio of stocks, including a position in pharmaceutical company AbbVie.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Tema Etfs LLC's increased stake in AbbVie reflects the continued investor interest in large-cap healthcare stocks, particularly those with diverse product pipelines and strong market positions. As AbbVie navigates industry challenges and opportunities, its performance will remain a closely watched indicator for healthcare-focused investors.